Identification of a ternary protein-complex as a therapeutic target for K-Ras-dependent colon cancer

Oncotarget

Volumn 5, Issue 12, 2014, Pages 4269-4282

  Qi, Xiaomei ^a   Xie, Congying ^b   Hou, Songwang ^a   Li, Gang ^b   Yin, Ning ^a   Dong, Lei ^b   Lepp, Adrienne ^a   Chesnik, Marla A ^a   Mirza, Shama P ^a   Szabo, Aniko ^a   Tsai, Susan ^a   Basir, Zainab ^a   Wu, Shixiu ^b,c   Chen, Guan ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b WENZHOU MEDICAL UNIVERSITY   (China)

^c ZHEJIANG CANCER HOSPITAL   (China)

Author keywords

Colon cancer; Hsp90; K Ras; p38 MAPK; Ternary complex; Therapeutic target

Indexed keywords

HEAT SHOCK PROTEIN 90; K RAS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 12; RAS PROTEIN;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; CELL MUTANT; COLON CANCER; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; METASTASIS POTENTIAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STABILITY; PROTEIN TARGETING; PROTEOMICS; WILD TYPE; CELL TRANSFORMATION; COLON TUMOR; GENETIC TRANSFECTION; GENETICS; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; COLONIC NEOPLASMS; HUMANS; PHOSPHORYLATION; RAS PROTEINS; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84905098265     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2001     Document Type: Article

References (60)

1. Downward J: Targeting Ras signalling pathways in cancer therapy. Nature Rev Cancer 2003, 3: 11-22.
2. Prior IA, Lewis PD, Mattos C: A comprehensive survey of ras mutations in cancer. Cancer Res 2012, 72: 2457-2467.
3. Malumbres M, Barbacid M: Ras oncogenes: the first 30 years. Nature Rev Cancer 2003, 3: 7-13.
4. Gysin S, Salt M, Young A, McCormick F: Therapeutic strategies for targeting Ras proteins. Genes & Cancer 2011, 2: 359-372.
5. Tanaka M, Omura K, Watanabe Y, Oda Y, Nakanishi I: Prognostic factors of colorectal cancer: K-ras mutation, overexpression of the p53 protein and cell proliferative activity. J Surg Oncol 1994, 57: 57-64.
6. Khambata-Ford S, Garrett CR, Neropol NJ, Basik M, Harbison CT, Wu S, Wong TW, Huang X, Takimoto CH, Godwin AK et al: Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 2007, 25: 3230-3237.
7. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S et al: K-ras mutations and benefit from Cetuximab in advanced colorectal cancer. N Engl J Med 2008, 359: 1757-1765.
8. Little AS, Balmanno K, Sale MJ, Newman S, Dry JR, Hampson M, Edwards PAW, Smith PD, Cook SJ: Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci Signal 2011, 4: ra17.
9. Yoon J, Koo K, Choi K: MEK1/2 inhibitors AS703026 and AZ6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy. Cancer Res 2011, 71: 445-553.
10. Blagosklonny MV: Hsp90-90-associated oncoproteins: multiple targets of geldanamycin and its analogs. Leukemia 2002, 16: 455-462.
11. Xu W, Trepel J, Neckers L: Ras, ROS and proteltoxic stress: a delicate balance. Cancer Cell 2011, 20: 281-282.
12. Scaltriti M, Dawood S, Cortes J: Molecular pathways: targeting Hsp90-who benefits and who does not. Clin Cancer Res 2012, 18: 4508-4513.
13. Karnoub AE, Weinberg RA: Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008, 9: 517-531.
14. Chen G, Hitomi M, Han J, Stacey DW: The p38 pathway provides negative feedback to Ras proliferative signaling. J Biol Chem 2000, 275: 38973-38980.
15. Bulavin DV, Demidov ON, Saito S, Kauraniemi P, Phillips C, Amundson SA, Ambrosino C, Sauter G, Nebreda AR, Anderson CW et al: Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nature Genet 2002, 31: 210-215.
16. Dolado I, Swat A, Ajenjo N, De Vita G, Cuadrado A, Nebreda AR: p38a MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell 2007, 11: 191-205.
17. Tang J, Qi X, Mercola D, Han J, Chen G: Essential role of p38g in K-Ras transformation independent of phosphorylation. J Biol Chem 2005, 280: 23910-23917.
18. Qi X, Tang J, Loesch M, Pohl N, Alkan S, Chen G: p38g MAPK integrates signaling cross-talk between Ras and estrogen receptor to increase breast cancer invasion. Cancer Res 2006, 66: 7540-7547.
19. Qi X, Pohl NM, Loesch M, Hou S, Li R, Qin JZ, Cuenda A, Chen G: p38a antagonizes p38g activity through c-Jun-dependent ubiquitin-proteasome pathways in regulating Ras transformation and stress response J Biol Chem 2007, 282:31398-31408.
20. Hou SW, Zhi H, Pohl N, Loesch M, Qi X, Li R, Basir Z, Chen G: PTPH1 dephosphorylates and cooperates with p38g MAPK to increases Ras oncogenesis through PDZ-mediated interaction. Cancer Res 2010, 70: 2901-2910.
21. Kyriakis JM, Avruch J: Mammalian MAPK signal transduction pathways activated by stress and inflammation: a 10-year update. Physiol Rev 2012, 92: 689-737.
22. Hou S, Padmanaban S, Qi X, Leep A, Mirza S, Chen G: p38g MAPK signals through phosphorylating its phosphatase PTPH1 in regulating Ras oncogenesis and stress response. J Biol Chem 2012, 287: 27895-27905.
23. Loesch M, Zhi H, Hou S, Qi X, Li R, Basir Z, Iftner T, Cuenda A, Chen G: p38g MAPK cooperates with c-Jun in trans-activating matrix metalloproteinase 9. J Biol Chem 2010, 285: 15149-15158.
24. Qi X, Zhi H, Lepp A, Wang P, Huang J, Basir Z, Chitambar CR, Myers CR, Chen G: p38g mitogen-activated protein kinase (MAPK) confers breast cancer hormone sensitivity by switching estrogen receptor (ER) signaling from classical to nonclassical pathway via stimulating ER phosphorylation and c-Jun transcription. J Biol Chem 2012, 287: 14681-14691.
25. Rosenthal DT, Lyer H, Escudero S, Bao L, Wu Z, Ventura AC, Kleer CG, Arruda EM, Garikipati K, Merajver SD: p38g promotes breast cancer motility and metastasis through regulation of RhoC GTPase, cytoskeletal architecture, and a novel leading edge behavior. Cancer Res 2011, 71 6338-6349
26. Meng F, Zhang H, Liu G, Kreike B, Chen W, Sethi S, Miller F, Wu G: p38g mitogen-activated protein kinase contributes to oncogenic properties maintenance and resistance to poly (ADP-ribose)-polymerase-1 inhibition in breast cancer Neoplasia 2011, 13:472-482.
27. Liu L, Liu Z, Jiang H, Zhang W, Qi S, Hu J, Wang X, Wu M: Gene expression profiles of hepatoma cell line HLE. World J Gastroenterol 2003, 9: 683-687.
28. Yang K, Liu Y, Liu Z, Liu Z, Liu X, Chen X, Zeng Y: p38g overexpression in gliomas and its role in proliferation and apoptosis. Scientific Rep 2013, 3: 1-5 DOI: 10.1038/srep02089.
29. Qi X, Hou S, Lepp A, Li R, Basir Z, Lou Z, Chen G: Phosphorylation and stabilization of topoisomerase IIa by p38g MAPK sensitize breast cancer cells to its poisons. J Biol Chem 2011, 286: 35883-35890.
30. Trepel J, Mollapour M, Giaccone G, Neckers L: Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 2010, 10: 537-549.
31. Taipale M, Jarosz D, Lindquist S: HSP90 at the hub of protein homeostasis: emerging mechanistic insights. Nat Rev Mol Cell Biol 2010, 11: 515-528.
32. Schulte TW, Blagosklonny MV, Ingui C, Neckers L: Disruption of the Raf-1-Hsp90 molecular complex results in destablization of Raf-1 and loss of Raf-1-Ras association. J Biol Chem 1995, 270: 24585-24588.
33. Whitesell L, Mimnaugh EG, Costa B, Myers CE, Neckers L: Inhibition of heat shock protein Hsp90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress protein in oncogenic transformation. Proc Natl Acad Sci USA 1994, 91: 8324-8328.
34. Dias SDR, Friedlos F, Light Y, Springer C, Workman P, Marais R: Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res 2005, 65: 10686-10691.
35. Grbovic OM, Basso AD, Sawai A, Ye Q, Friedlander P, Solit D, Rosen N: V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc Natl Acad Sci USA 2006, 103: 57-62.
36. Kamal A, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, Burrows FJ: A high-affinity conformation of Hsp90 confers tumor selectivity on Hsp90 inhibitors. Nature 2003, 425: 407-410.
37. Blagosklonny MV: Matching targets for selective cancer therapy. Drug Discov Today 2003, 8: 1104-1107.
38. Khalil A, Kabapy NF, Deraz SF, Smith C: Heat shock proteins in oncology: diagnostic biomarkers or therapeutic targets? Biochem Biophy Acta 2011, 1816:89-104.
39. Mollapour M, Tsutsumi S, Donnelly AC, Beebe K, Tokita MJ, Lee M, Lee S, Morra G, Bourboulia D, Scroggins BT et al: Swe1Wee1-dependent tyrosine phosphorylation of Hsp90 regulates distict facets of chaperone function. Mol Cell 2010, 37: 333-343.
40. Li Z, Jiang Y, Ulevitch RJ, Han J: The primary structure of p38g: a new member of p38 group of MAP kinases. Biochem Biophys Res Commun 1996, 228: 334-340.
41. Mollapour M, Tsutsumi S, Truman AW, Xu W, Vaughan CK, Beebe K, Konstantinova A, Vourganti S, Panaretou B, Piper PW et al: Threonine 22 phosphorylation attenuates hsp90 interaction with cochaperones and affects its chaperone activity. Mol Cell 2011, 41: 672-681.
42. Shirasawa S, Furuse M, Yokoyama N, Sasazuki T: Altered growth of human colon cancer cell lines disrupted at activated Ki-ras. Science 1993, 260: 85-88.
43. Matallanas D, Romano D, Al-Mulla F, O'Neill E, Al-Ali W, Crespo P, Doyle B, Nixon C, Sansom O, Drosten M et al: Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras. Mol Cell 2011, 44: 893-906.
44. Qi X, Tang J, Pramanik R, Schultz RM, Shirasawa S, Sasazuki T, Han J, Chen G: p38 MAPK activation selectively induces cell death in K-ras mutated human colon cancer cells through regulation of vitamin D receptor. J Biol Chem 2004, 279: 22138-22144.
45. Mollapour M, Neckers L: Post-translational modifications of Hsp90 and their contributions to chaperone regulation. Bioch Biophy Acta 2012, 1823: 648-655.
46. Songyang Z, Lu KP, Kwon YT, Tsai L, Filhol O, Cantley LC: A stuctural basis for substrate specificites of protein ser/thr kinases: primary sequence preference of casei kinases 1 and II, NIMA, phosphrylase kinase, calmodulin-dependent kinase II, CDK5, and Erk1 Mol Cell Biol 1996, 16:6486-6493.
47. Ozes O, Blatt LM, Seiwert SD: Use of pirfenidone in therapeutic regimens. United States Patent-US 7,407,973 B2 2008, Aug. 5th:1-46.
48. Cain WC, Stuart RW, Lefkowitz DL, Starnes JD, Margolin S, Lefkowitz SS: Inhibition of tumor necrosis factor and subsequent endotoxin shock by pirfenidone. Int J Immunopharmacol 1998, 20: 685-695.
49. Richeldi L, Yasothan U, Kirkpatrick DS: Pirfenidone. Nature Reviews/Drug Disconvery 2011, 10: 489-490.
50. Noble PW, Albera C, Bradford W, Costabel U, Glassberg MK, Kardatzke D, King TE, Lancaster Jea: Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet 2011, 377: 1760-1769.
51. Schaefer CJ, Ruhrmund DW, Pan L, Selwert SD, Kossen K: Antifibrotic activities of pirfenidone in animal models. Eur Respir Rev 2011, 20: 85-97.
52. Moran N: p38 kinase inhibitor approved for idiopathic pulmonary fibrosis. Nat Biotechnol 2011, 29: 301.
53. Blagosklonny MV: Overcoming limitations of natural anticancer drugs by combining with artificial agents. Trends Pharmacological Sci 2005, 26: 77-81.
54. Demidenko ZN, An WG, Lee JT, Romanova LY, McCubrey JA, Blagosklonny MV: Kinase-addiction and bi-phasic sensitity-resistance of bcr-abl and raf-1-expressing cells to imatinib and geldanamycin Cancer Biol Ther 2005, 4:484-490.
55. Dogan T, Harms GS, Hekman M, Karreman C, Oberoi TK, Alnemri ES, Rapp UR, Rajalingam K: X-linked and cellular IAPs modulate the stability of C-RAF kinase and cell motility. Nat Cell Biol 2008, 10: 1447-1455.
56. Chen G, Oh S, Monia BP, Stacey DW: Antisense oligonucleotides demonstrate a dominant role of c-Ki-RAS proteins in regulating the proliferation of diploid human fibroblasts. J Biol Chem 1996, 271: 28259-28265.
57. Kopp F, Wagner E, Roidl A: The proto-oncogene KRAS is targeted by mtR-200c. Oncotarget 2014, 5: 185-195.
58. Blagosklonny MV, Toretsky J, Bohen S, Neckers L: Mutant conformation of p53 translated in vitro or in vivo requires functional Hsp90. Proc Natl Acad Sci USA 1996, 93: 8379-8363.
59. Demidenko ZN, Vivo C, Halicka HD, Li CJ, Bhalla K, Brounde EU, Blagosklonny MV: Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection. Cell Death Differ 2006, 13: 1434-1441.
60. Azoitei N, Hoffmann CM, Ellegast JM, Ball CR, Obermayer K, GoBele Uea: Targeting of KRAS mutant tumors by HSP90 inhibitors involves degradation of STK33. J Exp Med 2012, 209: 697.